Rimonabant (also known as SR141716; trade names Acomplia, Zimulti) is an anorectic antiobesity drug approved in Europe in 2006 but was withdrawn worldwide...

receptor antagonists. The first CBR inverse agonist, rimonabant, was described in 1994. Rimonabant blocks the CB1 receptor selectively and has been shown...

at the CB1 cannabinoid receptor. AM-251 is structurally very close to rimonabant; both are biarylpyrazole cannabinoid receptor antagonists. In AM-251,...

oxaloacetate supplements had no effect on lifespan in healthy laboratory mice. Rimonabant (Acomplia) is an anti-obesity drug initially approved for use in the European...

cannabis), increased appetite. However, some drugs in this class such as rimonabant were withdrawn or ceased development to concerns about mental health and...

seen with an antagonist. An example is the cannabinoid inverse agonist rimonabant. A superagonist is a term used by some to identify a compound that is...

The antihypertensive effect of Spilanthol was blocked by CB1 antagonist Rimonabant and TRPV1 antagonist Capsazepine suggesting Spilanthol mediates some activity...

Protriptyline Proparacaine Quetiapine Ramelteon Rasagiline Reboxetine Ribavirin Rimonabant Risperidone Rivastigmine Rofecoxib Ropinirole Rotigotine Rufinamide Selegiline...

drugs that were ever approved by the FDA. Some of them (lumiracoxib, rimonabant, tolrestat, ximelagatran and ximelidine, for example) were approved to...

adverse cardiovascular risk profile. Similarly, the appetite suppressant rimonabant (a cannabinoid receptor antagonist) had to be withdrawn when it was linked...